Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.
Jiangxi Institute of Biological Products Total Payout Yield % Explanation
Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.
Jiangxi Institute of Biological Products Total Payout Yield % Related Terms
Jiangxi Institute of Biological Products Total Payout Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangxi Institute of Biological Products Total Payout Yield % Chart
Jiangxi Institute of Biological Products Annual Data
Trend
Dec23
Dec24
Dec25
Total Payout Yield %
0.00
0.00
0.00
Jiangxi Institute of Biological Products Semi-Annual Data
Dec23
Dec24
Dec25
Total Payout Yield %
0.00
0.00
0.00
HKSE:06915 vs LLY, JNJ, ABBV: Total Payout Yield % Comparison
For the Drug Manufacturers - General subindustry, Jiangxi Institute of Biological Products's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangxi Institute of Biological Products Total Payout Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangxi Institute of Biological Products's Total Payout Yield % distribution charts can be found below:
* The bar in red indicates where Jiangxi Institute of Biological Products's Total Payout Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangxi Institute of Biological Products (HKSE:06915) has a Total Payout Yield % of 0.00 as of Sep. 10, 2026. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on Jiangxi Institute of Biological Products and its competitors.
Is Jiangxi Institute of Biological Products' Total Payout Yield % too high?
Jiangxi Institute of Biological Products' current Total Payout Yield % is 0.00. Overall, Jiangxi Institute of Biological Products has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Jiangxi Institute of Biological Products' Total Payout Yield % compare to LLY and JNJ?
Jiangxi Institute of Biological Products' Total Payout Yield % of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Yield % for a Drug Manufacturers company?
A good Total Payout Yield % depends on the Drug Manufacturers industry context. However, Total Payout Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Yield % mean?
A high Total Payout Yield % can signal that a stock is expensive relative to its fundamentals. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on Jiangxi Institute of Biological Products and its competitors. Jiangxi Institute of Biological Products's current Total Payout Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangxi Institute of Biological Products stock overvalued right now?
Jiangxi Institute of Biological Products (HKSE:06915) has a current Total Payout Yield % of 0.00. The current Total Payout Yield % is 0.00. Jiangxi Institute of Biological Products' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Yield % calculated?
Total Payout Yield % is calculated from a company's financial statements. For Jiangxi Institute of Biological Products (HKSE:06915), the current Total Payout Yield % is 0.00 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jiangxi Institute of Biological Products Inc is principally engaged in the business of research and development, and production and sale of human tetanus antitoxin. It operates as the provider and exporter of Human TAT in China and an antiserum platform company. Its products include biological products containing immunoglobulins or immunoglobulin F(ab')2 fragments, which are used in medical applications such as tetanus, snakebite envenoming, and rabies treatment. The majority of the company's revenue is derived from the sale of Human Tetanus Antitoxin in the Chinese mainland.
23GF Score
Get the complete analysis for HKSE:06915
Total Payout Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06915 has been successfully added to your 
